The Scottish Medicines Consortium has also accepted restricted use of sorafenib for the same indication and if available with the discount agreed in the Patient Access Scheme.
Sorafenib has previously (2010) been rejected by the National Institute for Health and Care Excellence (NICE), but is currently available via the NHS England Cancer Drugs Fund (CDF).